Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD)
The Food and Drug Administration for clinical trials involving major depressive disorder and treatment-resistant depression granted psilocybin a “breakthrough therapy” status. The direct phosphorylation of psilocin to psilocybin that uses a fast crystallization associated with a kinetically controlled process resulted in a smaller particle size distribution.
The quest for an ideal crystallization process in the past has been enigmatic but has become a very commonly used separation process in many different industries, including materials and pharmaceutical industries. This article aims to investigate the applicability of a crystal engineering technique that improves the physicochemical properties of psilocybin API.
Read the below article to find out more.